

WEST

 Generate Collection

L2: Entry 11 of 29

File: JPAB

Apr 8, 1997

PUB-NO: JP409094065A

DOCUMENT-IDENTIFIER: JP 09094065 A

TITLE: TEA BEVERAGE CONTAINING AMYLASE INHIBITOR

PUBN-DATE: April 8, 1997

INVENTOR-INFORMATION:

NAME	COUNTRY
KARITA, KANAKO	
YOSHIDA, MIEKO	

ASSIGNEE-INFORMATION:

NAME	COUNTRY
NISSHIN FLOUR MILLING CO LTD	

APPL-NO: JP07273677

APPL-DATE: September 28, 1995

INT-CL (IPC): A23 F 3/16; A23 L 2/70; C12 N 9/99

ABSTRACT:

PROBLEM TO BE SOLVED: To obtain the subject tea beverage for prevention and treatment, etc., of suppression of blood glucose level, diabetes mellitus, hypertension, arteriosclerosis and obesity, etc., having a pH value within a specific acidic range in water solution state and suppressing decomposition of starch to sugar by blending an amylase inhibitor.

SOLUTION: This tea beverage contains an amylase inhibitor. The tea beverage is obtained by dissolving powdery wheat tea, etc., in water at 25°C, adding an amylase inhibitor having an amino acid sequence separated from wheat flour and expressed by the formula so as to be $\geq 2000V/ml$ based on total weight of an aqueous solution of, tea beverage before blending the amylase inhibitor, stirring these components to afford the wheat tea beverage containing amylase inhibitor (having pH 6.5), adding at least one kind of acid selected from lactic acid, citric acid, tartaric acid, malic acid, acetic acid, ascorbic acid, etc., as a pH adjuster thereto and controlling pH in a state of water solution to a range of 3.8 to 5.4. The tea beverage suppresses decomposition of starch to sugar and is effective for preventing and treating blood glucose level, diabetes mellitus, hypertension, arteriosclerosis and obesity, etc.

COPYRIGHT: (C)1997,JPO

WEST

 [Generate Collection](#) [Print](#)

L2: Entry 27 of 29

File: DWPI

Oct 5, 1993

DERWENT-ACC-NO: 1993-348354

DERWENT-WEEK: 199344

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Liq. compsn. for treating obesity and constipation - contain edible fibre and lactic acid

PATENT-ASSIGNEE:

ASSIGNEE	CODE
MIYARISAN SEIBUTSU IGAKU KENKYUSHO KK	MIYAN

PRIORITY-DATA: 1992JP-0010919 (January 24, 1992)**PATENT-FAMILY:**

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 05255097 A	October 5, 1993		005	A61K035/74

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
JP 05255097A	January 24, 1992	1992JP-0010919	

INT-CL (IPC): A23L 1/30; A23L 1/308; A61K 9/08; A61K 31/70; A61K 31/715; A61K 35/74; A61K 35/78**ABSTRACTED-PUB-NO:** JP 05255097A**BASIC-ABSTRACT:**

The liq. compsn. contains (1) edible fibre, and (2) lactic acid. Pref. lactic acid is Clostridium butyricum NIP 1006; Clostridium butyricum NIP 1015; Clstridium butyricum NIP 1017; and/or Clostridium butyricum Miyairi 588.

The edible fibre is cellulose, hemi-cellulose, ligane, pectin, guar gum, glucomannan, glacto-mannan, carraginin, CMC, arginic acid or its salt and deriv., chitosan, corn bran, wheat bran, yellow pea fibre, orange fibre, chitin, collagen or chondroitin sulphate. The compsn. is forme dinto foods contg. 1 g of edible fibre and 3.3×10^2 to 1×10^1 g of lactic acid or into medicine contg. 1 g of fibre, and 3.3×10^4 to 1×10^1 g of lactic acid.

USE - The liq. compsn. is used for prevention and therapy of constipation and obesity.

In an example, gluco-mannan (30 g) was added to water (1000 ml) and stirred to form juice. Maltitol (100g) orange juice power (50 g), orange flavour (3 ml), vitamin C (10 g), citric acid (1 g), sodium citrate (1 g), lactic acid powder (0.1 g: 1×10^1 g) were added to the juice to form orange juice. The juice (120 ml) was filled in a glass bottle and air-tightly sealed.

CHOSEN-DRAWING: Dwg.0/0**TITLE-TERMS:** LIQUID COMPOSITION TREAT OBESITY CONSTIPATION CONTAIN EDIBLE FIBRE

LACTIC ACID

DERWENT-CLASS: B05 D13

CPI-CODES: B04-A07D2; B04-B04A6; B04-C02; B10-C04D; B12-J02; B12-J07; D03-H01T;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

M423 M431 M782 M903 P731 P737 Q211 V400 V404 V752

Chemical Indexing M1 *02*

Fragmentation Code

M423 M431 M782 M903 M904 M910 P731 P737 Q211 V0

V711

Specfic Compounds

01852M

Chemical Indexing M1 *03*

Fragmentation Code

J0 J011 J1 J111 J2 J211 K0 L8 L811 L815

L816 L817 L818 L831 L832 M210 M211 M272 M280 M281

M320 M423 M431 M782 M903 M904 P731 P737 Q211 V735

Specfic Compounds

17032M

Chemical Indexing M1 *04*

Fragmentation Code

K0 L8 L815 L816 L831 M423 M431 M782 M903 M904

P731 P737 Q211 V735

Specfic Compounds

03104M

Chemical Indexing M1 *05*

Fragmentation Code

K0 L8 L814 L815 L831 M423 M431 M782 M903 P731

P737 Q211 V735

Chemical Indexing M1 *06*

Fragmentation Code

K0 K4 K421 K499 L8 L814 L815 L831 M423 M431

M782 M903 P731 P737 Q211 V735

Chemical Indexing M1 *07*

Fragmentation Code

H5 H521 H8 J0 J011 J1 J171 M280 M311 M321

M342 M381 M391 M423 M431 M782 M903 M904 M910 P731

P737 Q211 V0 V713

Specfic Compounds

01835M

Chemical Indexing M1 *08*

Fragmentation Code

J0 J011 J1 J111 M423 M431 M630 M782 M903 M904

M910 P731 P737 Q211 V0 V733

Specfic Compounds

01866M 07226M

Chemical Indexing M1 *09*

Fragmentation Code

J0 J011 J3 J321 K0 L8 L814 L834 M210 M211

M262 M281 M320 M423 M431 M782 M903 M904 P731 P737

Q211 V735

Specfic Compounds

03233M

Chemical Indexing M1 *10*
Fragmentation Code
J0 J011 J1 J111 J321 K0 K4 K421 M423 M431
M782 M903 M904 M910 P731 P737 Q211 V0 V731
Specfic Compounds
01875M

Chemical Indexing M1 *12*
Fragmentation Code
M423 M431 M782 M903 P731 P737 Q211 V500 V540

Chemical Indexing M2 *11*
Fragmentation Code
H4 H401 H481 H8 J0 J011 J1 J171 M280 M312
M321 M331 M340 M342 M349 M381 M391 M416 M431 M620
M782 M903 M904 M910 P731 P737 Q211
Specfic Compounds
00009M

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0009U; 1835U; 1852U; 1866U; 1875U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1993-154509